No abstract available
MeSH terms
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cell Transformation, Neoplastic / genetics
-
Combined Modality Therapy
-
Core Binding Factor Alpha 2 Subunit / genetics
-
DNA (Cytosine-5-)-Methyltransferase 1 / antagonists & inhibitors
-
Dasatinib / administration & dosage
-
Dasatinib / pharmacology
-
Decitabine / administration & dosage
-
Decitabine / pharmacology
-
Female
-
Gain of Function Mutation
-
Hematopoietic Stem Cell Transplantation
-
Hodgkin Disease / drug therapy
-
Hodgkin Disease / genetics*
-
Hodgkin Disease / radiotherapy
-
Humans
-
Infant
-
Leukemia, Myeloid, Acute / genetics*
-
Molecular Targeted Therapy
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / genetics
-
Neoplasms, Second Primary / genetics*
-
Neoplasms, Second Primary / therapy
-
Oncogene Proteins, Fusion / genetics
-
Primary Immunodeficiency Diseases / complications*
-
Proto-Oncogene Proteins c-kit / antagonists & inhibitors
-
Proto-Oncogene Proteins c-kit / genetics
-
RUNX1 Translocation Partner 1 Protein / genetics
-
Radiotherapy, Adjuvant
-
Receptors, CXCR4 / genetics
-
Remission Induction
-
Warts / complications*
Substances
-
AML1-ETO fusion protein, human
-
Antimetabolites, Antineoplastic
-
CXCR4 protein, human
-
Core Binding Factor Alpha 2 Subunit
-
Neoplasm Proteins
-
Oncogene Proteins, Fusion
-
RUNX1 Translocation Partner 1 Protein
-
Receptors, CXCR4
-
Decitabine
-
DNA (Cytosine-5-)-Methyltransferase 1
-
DNMT1 protein, human
-
KIT protein, human
-
Proto-Oncogene Proteins c-kit
-
Dasatinib